{"count": 5, "results": [{"_id": "25901291", "pmid": 25901291, "pmcid": "PMC4401166", "title": "Metformin attenuates myocardial remodeling and neutrophil recruitment after myocardial infarction in rat", "journal": "Bioimpacts", "authors": ["Soraya H", "Rameshrad M", "Mokarizadeh A", "Garjani A"], "date": "2015-01-01T00:00:00Z", "doi": "10.15171/bi.2015.02", "meta_date_publication": "2015", "meta_volume": "5", "meta_issue": "1", "meta_pages": "3-8", "score": 50072.105, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ attenuates @<m>DISEASE_Atrial_Remodeling</m> @DISEASE_MESH:D064752 @@@myocardial remodeling@@@ and neutrophil recruitment after @DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@myocardial infarction@@@ in rat", "citations": {"NLM": "Soraya H, Rameshrad M, Mokarizadeh A, Garjani A. Metformin attenuates myocardial remodeling and neutrophil recruitment after myocardial infarction in rat Bioimpacts. 2015;5(1):3-8. PMID: 25901291", "BibTeX": "@article{25901291, title={Metformin attenuates myocardial remodeling and neutrophil recruitment after myocardial infarction in rat}, author={Soraya H and Rameshrad M and Mokarizadeh A and Garjani A}, journal={Bioimpacts}, volume={5}, number={1}, pages={3-8}}"}}, {"_id": "29478240", "pmid": 29478240, "title": "Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction.", "journal": "Am J Cardiovasc Drugs", "authors": ["Varjabedian L", "Bourji M", "Pourafkari L", "Nader ND"], "date": "2018-06-01T00:00:00Z", "doi": "10.1007/s40256-018-0266-3", "meta_date_publication": "2018 Jun", "meta_volume": "18", "meta_issue": "3", "meta_pages": "181-193", "score": 50056.254, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ preconditions the heart against @DISEASE_Ischemia @DISEASE_MESH:D007511 @@@ischemia@@@-@DISEASE_Reperfusion_Injury @DISEASE_MESH:D015427 @@@reperfusion injury@@@ and may improve @<m>DISEASE_Atrial_Remodeling</m> @DISEASE_MESH:D064752 @@@myocardial remodeling@@@ after an @DISEASE_Brain_Ischemia @DISEASE_MESH:D002545 @@@ischemic@@@ insult. ", "citations": {"NLM": "Varjabedian L, Bourji M, Pourafkari L, Nader ND. Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction. Am J Cardiovasc Drugs. 2018 Jun;18(3):181-193. PMID: 29478240", "BibTeX": "@article{29478240, title={Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction.}, author={Varjabedian L and Bourji M and Pourafkari L and Nader ND}, journal={Am J Cardiovasc Drugs}, volume={18}, number={3}, pages={181-193}}"}}, {"_id": "30998979", "pmid": 30998979, "title": "Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction.", "journal": "J Mol Cell Cardiol", "authors": ["Asensio-Lopez MC", "Lax A", "Fernandez Del Palacio MJ", "Sassi Y", "Hajjar RJ", "Januzzi JL", "Bayes-Genis A", "Pascual-Figal DA"], "date": "2019-05-01T00:00:00Z", "doi": "10.1016/j.yjmcc.2019.04.009", "meta_date_publication": "2019 May", "meta_volume": "130", "meta_issue": "", "meta_pages": "216-233", "score": 50044.95, "text_hl": "CONCLUSION: The @GENE_RORB @GENE_309288 @@@transcription factor@@@ @GENE_YY1 @GENE_24919 @@@Yy1@@@ regulates sST2 expression, and repression of @GENE_YY1 @GENE_24919 @@@Yy1@@@ by @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ results in lower levels of sST2 that are associated with favorable @<m>DISEASE_Atrial_Remodeling</m> @DISEASE_MESH:D064752 @@@myocardial remodeling@@@. ", "citations": {"NLM": "Asensio-Lopez MC, Lax A, Fernandez Del Palacio MJ, Sassi Y, Hajjar RJ, Januzzi JL, Bayes-Genis A, Pascual-Figal DA. Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction. J Mol Cell Cardiol. 2019 May;130():216-233. PMID: 30998979", "BibTeX": "@article{30998979, title={Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction.}, author={Asensio-Lopez MC and Lax A and Fernandez Del Palacio MJ and Sassi Y and Hajjar RJ and Januzzi JL and Bayes-Genis A and Pascual-Figal DA}, journal={J Mol Cell Cardiol}, volume={130}, pages={216-233}}"}}, {"_id": "20873243", "pmid": 20873243, "title": "[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].", "journal": "Ter Arkh", "authors": ["Onuchin SG", "Elsukova OS", "Solov'ev OV", "Onuchina EL"], "date": "2010-01-01T00:00:00Z", "meta_date_publication": "2010", "meta_volume": "82", "meta_issue": "8", "meta_pages": "34-41", "score": 50044.914, "text_hl": "When @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ was used in combination with gliclaside (Group 2) for 12 months, there was the maximum @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@IR@@@ reduction, an increase in @GENE_INS @GENE_3630 @@@insulin@@@ sensitivity, and better results in reaching the goal values of @CHEMICAL_Carbohydrates @CHEMICAL_MESH:D002241 @@@carbohydrate@@@ metabolism; there was left ventricular @<m>DISEASE_Atrial_Remodeling</m> @DISEASE_MESH:D064752 @@@myocardial reverse remodeling@@@. ", "citations": {"NLM": "Onuchin SG, Elsukova OS, Solov'ev OV, Onuchina EL. [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. Ter Arkh. 2010;82(8):34-41. PMID: 20873243", "BibTeX": "@article{20873243, title={[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].}, author={Onuchin SG and Elsukova OS and Solov'ev OV and Onuchina EL}, journal={Ter Arkh}, volume={82}, number={8}, pages={34-41}}"}}, {"_id": "29753686", "pmid": 29753686, "title": "Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCalpha/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction.", "journal": "Transl Res", "authors": ["Asensio-Lopez MDC", "Lax A", "Fernandez Del Palacio MJ", "Sassi Y", "Hajjar RJ", "Pascual-Figal DA"], "date": "2018-09-01T00:00:00Z", "doi": "10.1016/j.trsl.2018.04.004", "meta_date_publication": "2018 Sep", "meta_volume": "199", "meta_issue": "", "meta_pages": "4-23", "score": 50043.957, "text_hl": "The use of specific inhibitors or small interference RNA provided evidence that @GENE_PRKCA @GENE_24680 @@@PKCalpha@@@ is downstream of mitoNox, and that the activation of this pathway results in @GENE_LGALS3 @GENE_83781 @@@Gal-3@@@ upregulation.The @GENE_LGALS3 @GENE_83781 @@@Gal-3@@@ secreted by cardiomyocytes has a paracrine effect on cardiac fibroblasts, inducing their activation. In conclusion, a @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@-induced increase in @GENE_PRKAA2 @GENE_78975 @@@AMPK@@@ improves @<m>DISEASE_Atrial_Remodeling</m> @DISEASE_MESH:D064752 @@@myocardial remodeling@@@ post-MI, which is related to the inhibition of the mitoNox/@GENE_PRKCA @GENE_24680 @@@PKCalpha@@@/@GENE_LGALS3 @GENE_83781 @@@Gal-3@@@ pathway. ", "citations": {"NLM": "Asensio-Lopez MDC, Lax A, Fernandez Del Palacio MJ, Sassi Y, Hajjar RJ, Pascual-Figal DA. Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCalpha/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction. Transl Res. 2018 Sep;199():4-23. PMID: 29753686", "BibTeX": "@article{29753686, title={Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCalpha/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction.}, author={Asensio-Lopez MDC and Lax A and Fernandez Del Palacio MJ and Sassi Y and Hajjar RJ and Pascual-Figal DA}, journal={Transl Res}, volume={199}, pages={4-23}}"}}]}